4521
KAKEN PHARMACEUTICAL CO.,LTD.
科研製薬
- Industry
- Pharmaceutical
- Market
- Prime
- Accounting standards
- Japanese GAAP
- Consolidation basis
- Consolidated
Key metrics
Revenue(million JPY)
Mar 2021
74,979
Mar 2022
76,034
Mar 2023
72,984
Mar 2024
72,044
Mar 2025
94,035
Operating profit(million JPY)
Mar 2021
17,788
Mar 2022
17,064
Mar 2023
7,998
Mar 2024
9,513
Mar 2025
21,034
Operating profit margin(%)
Mar 2021
23.72
Mar 2022
22.44
Mar 2023
10.96
Mar 2024
13.2
Mar 2025
22.37
Profit before tax(million JPY)
Mar 2021
18,657
Mar 2022
13,885
Mar 2023
6,817
Mar 2024
9,796
Mar 2025
19,435
Profit(million JPY)
Mar 2021
13,405
Mar 2022
9,549
Mar 2023
5,440
Mar 2024
8,025
Mar 2025
13,945
Total assets(million JPY)
Mar 2021
163,332
Mar 2022
165,181
Mar 2023
166,328
Mar 2024
171,623
Mar 2025
190,422
Cash and cash equivalents(million JPY)
Mar 2021
77,305
Mar 2022
74,625
Mar 2023
74,260
Mar 2024
65,325
Mar 2025
70,085
Cash flows from operating activities(million JPY)
Mar 2021
14,380
Mar 2022
13,336
Mar 2023
9,253
Mar 2024
2,577
Mar 2025
29,780
Cash flows from investing activities(million JPY)
Mar 2021
-1,644
Mar 2022
-7,888
Mar 2023
-2,627
Mar 2024
-5,854
Mar 2025
-19,650
Cash flows from financing activities(million JPY)
Mar 2021
-8,752
Mar 2022
-8,129
Mar 2023
-6,990
Mar 2024
-5,658
Mar 2025
-5,369
Return on equity(%)
Mar 2021
10.1
Mar 2022
7
Mar 2023
4
Mar 2024
5.7
Mar 2025
9.4
Equity ratio(%)
Mar 2021
83.4
Mar 2022
83.4
Mar 2023
81.9
Mar 2024
83.8
Mar 2025
80.2
Earnings per share(JPY per share)
Mar 2021
347.37
Mar 2022
251.43
Mar 2023
144.8
Mar 2024
212.67
Mar 2025
365.42
Net assets per share(JPY per share)
Mar 2021
3,555.93
Mar 2022
3,642.34
Mar 2023
3,636.17
Mar 2024
3,796.05
Mar 2025
3,974.47
Dividend per share(JPY per share)
Mar 2021
150
Mar 2022
150
Mar 2023
150
Mar 2024
150
Mar 2025
190
Payout ratio(%)
Mar 2021
43.18
Mar 2022
59.66
Mar 2023
103.59
Mar 2024
70.53
Mar 2025
51.99
Disclaimer
The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.
The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.